Clinical trials: Hepatocarcinoma
Unresectable Hepatocellular Carcinoma
Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study
This investigation will be conducted to collect information of safety in patients with unresectable hepatocellular carcinoma (HCC) treated with the combination therapy of IMJUDO 25 mg, 300 mg and IMFINZI Intravenous Infusion 120…
- Trial name
- NCT05667064
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca
Hepatocarcinoma
HCC Innervation Assessment
Primary liver cancer casualties are ranked 3rd worldwide and are still on the rise despite the recent advent of adequate hepatitis B and C therapies.
- Trial name
- NCT06886763
- Testing
- Liver innervation markers
- Where
- 2 sites in Egypt, France
- Volunteers
- 300 people
- Sponsor
- Hospices Civils de Lyon
Hepatocellular Carcinoma (HCC)
Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer
This study is for people with unresectable or advanced hepatocellular carcinoma who have not received previous systemic treatment for liver cancer. The study will compare lenvatinib plus tislelizumab with or without gefitinib.
- Trial name
- LENTIG-HCC (NCT07829926)
- Testing
- Lenvatinib, Tislelizumab, Gefitinib
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Hepatocellular Carcinoma
The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs
This cohort study aims to evaluate the validation of general evaluation score in the prediction of hepatocellular carcinoma risk among patients with advanced fibrosis (F3) and cirrhosis (F4) who achieved sustained virological…
- Trial name
- NCT06325826
- Testing
- General Evaluation Score (GES)
- Where
- Egypt
- Volunteers
- 500 people
- Sponsor
- Egyptian Liver Hospital
Hepatocellular Carcinoma
Combine TACE and RFA Versus TACE Alone for HCC With PVTT
The purpose of this study is to determine whether combined radiofrequency ablation and transcatheter chemoembolization (TACE) result in better survival outcomes than TACE alone in patients with HCC and portal vein tumor thrombus.
- Trial name
- CORTT (NCT02301091)
- Testing
- TACE, RFA, pirarubicin,mitomycin and lobaplatin
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Ming Zhao
Solid Tumor, Adult, Solid Tumor
Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent
This clinical trial is designed as a multi-center, open-label, dose-escalation, dose-expansion, phase 1 clinical trial and will be evaluating the safety and efficacy of PB101 in patients with advanced solid tumors who have…
- Conditions
- Solid Tumor, Adult, Solid Tumor, Gastric Cancer, Hepatocellular Carcinoma
- Trial name
- NCT06075849
- Testing
- PB101
- Where
- 3 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Panolos Bioscience
Liver Transplant; Complications, Hepatocarcinoma
Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation
1. Explore the impact of postoperative administration of multi-kinase inhibitors (including sorafenib, lenvatinib, and regorafenib) in conjunction with bevacizumab on post-transplant recurrence, overall survival, and drug safety…
- Conditions
- Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma, High-Risk Cancer
- Trial name
- NCT06041490
- Testing
- multi-kinase inhibitors in combination with bevacizumab
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Peking Union Medical College Hospital
Bleeding Esophageal Varices, Hepatocellular Carcinoma
Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices
Randomized comparison within the endoscopic esophageal varices ligation versus non-selective beta-blocker in the primary prevention of esophageal variceal bleeding in patients with HCC.
- Trial name
- P-HCC (NCT01970748)
- Testing
- Propranolol, Esophageal variceal ligation
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Hepatocellular Carcinoma
Yang Yin Fu Zheng Therapy in HBV Associated Hepatocellular Carcinoma
Clinical research of Yang Yin Fu Zheng therapy in HBV associated hepatocellular carcinoma basing on immune microenviroment.The purpose of this study is to observe the efficacy of routine medical care combined with Yang Yin Fu…
- Trial name
- YYFZTIHBVHCC (NCT02927626)
- Testing
- Yang Yin Fu Zheng therapy, Routine medical care
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Beijing Ditan Hospital
Pancreatic Cancer, Pancreas Cancer
Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies
In light of this new technology and preliminary findings of low toxicity of online, adaptive, magnetic resonance (M)-guided stereotactic radiation on a single arm prospective study, the investigators propose to compare this…
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Cancer of the Pancreas, Hepatocellular Carcinoma
- Trial name
- NCT02950025
- Testing
- Online, adaptive MR-guided SBRT, Online, non-adaptive MR-guided SBRT, European Organization for Research and Treatment of Cancer (EORTC) QLQ-30
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Liver Cancer, Liver Metastasis Colon Cancer
Clinical Validation of a Fractional Administration Device for Holmium-166 SIRT
To investigate the in vivo performance and safety of a novel medical device for the injection of holmium-166 microspheres during radioembolization.
- Conditions
- Liver Cancer, Liver Metastasis Colon Cancer, Primary Liver Cancer
- Trial name
- CONTROL (NCT05183776)
- Testing
- Fractional administration device
- Where
- Netherlands
- Volunteers
- 5 people
- Sponsor
- Radboud University Medical Center
HCC - Hepatocellular Carcinoma
Can Hepatic-splenic Elastography Predict the Risk of Hepatocellular Recurrence After Radiofrequency Ablation?
The study aims to assess whether there is an association between hepatic and splenic elastography values and the risk of HCC recurrence after treatment with RFA
- Trial name
- ELASTORFA (NCT06777017)
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hepatocellular Carcinoma
Allogeneic "Gammadelta T Cells (γδ T Cells)" Cell Immunotherapy in Phase 1 Hepatocellular Carcinoma Clinical Trial
This study aims to evaluate the safety, tolerability and efficacy of ex-vivo expanded allogeneic γδT cells obtained from a blood-related donor of hepatocellular carcinoma patients.
- Trial name
- NCT04518774
- Testing
- Ex-vivo expanded allogeneic γδT cells
- Where
- 2 sites in China
- Volunteers
- 8 people
- Sponsor
- Beijing 302 Hospital
Hepatocellular Carcinoma
Abbreviated MRI Using Gadoxetic Acid Versus CT for Surveillance of Recurrent HCC After Curative Treatment
Hepatocellular carcinoma (HCC) often has a poor prognosis after curative treatment due to frequent recurrence. Post-surgery, 60-70% of HCC patients experience recurrence, rising to 80% after ablation therapy.
- Trial name
- NCT06537193
- Testing
- AMRI, CT
- Where
- South Korea
- Volunteers
- 455 people
- Sponsor
- Asan Medical Center
Hepatocarcinoma, Pancreatic Tumor
METabolic PROFILE of Hepatocarcinoma and Pancreatic Tumors
Hepatic (hepatocellular carcinoma (HCC)) and pancreatic (pancreatic adenocarcinoma (ADKP); pancreatic neuroendocrine tumors (TNEP)) primary tumors are the most common malignant tumors of the hepato-bilio-pancreatic system and…
- Trial name
- PROMETHEP (NCT05794048)
- Testing
- Hepatocellular carcinoma, Pancreatic adenocarcinoma, Pancreatic neuroendocrine tumor
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma (HCC), Unresectable Hepatocellular Carcinoma
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Safety and Efficacy Evaluation of Tremelimumab Plus Durvalumab(MEDI4736) in Combination with Concurrent Transarterial Chemoembolization in Unresectable Hepatocellular carcinoma
- Trial name
- NCT06911255
- Testing
- Tremelimumab Plus Durvalumab (MEDI4736), Transarterial chemoembolization (TACE)
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- Yoon Jun Kim
Hepatocellular Carcinoma (HCC)
Immune Checkpoint Inhibitors and Anti-vascular Endothelial Growth Factor Antibody/Tyrosine Kinase Inhibitors With or Without HAIC for Unresectable HCC With Portal Vein Tumor Thrombosis
Anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors (VEGF/TKI-ICI) plus Immune checkpoint inhibitors (ICIs) are recommended for patients with unresectable hepatocellular carcinoma (HCC) with PVTT in China.
- Trial name
- NCT06881433
- Where
- China
- Volunteers
- 1,649 people
- Sponsor
- Zhongda Hospital
Carcinoma, Hepatocellular
TATE Versus TACE in Intermediate Stage HCC
An open label randomized study to compare TATE versus TACE in patients with intermediate stage Hepatocellular carcinoma who are not suitable for surgical resection or radiofrequency ablation.
- Trial name
- TATE (NCT03145558)
- Testing
- Tirapazamine, Doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Teclison Ltd.
Hepatocellular Carcinoma Non-resectable
Individualized Dosimetry for Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma
Patients with hepatocellular carcinoma often die from intrahepatic disease because current treatment options are limited. Local treatment using 166Ho-radioembolization (166Ho-RE) offers a safe and effective treatment.
- Trial name
- iHEPAR (NCT05114148)
- Testing
- Holmium-166 radioembolization
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- UMC Utrecht
Advanced Hepatocellular Carcinoma
Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy
This study plans to observe the changes of liver cancer and immune cell subsets by replicating the high abundance intestinal flora and liver cancer mouse model, reveal the relationship and mechanism of intestinal flora in the…
- Trial name
- NCT05620004
- Testing
- Bifidobacterium Bifidum Oral Product
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University